삼성서울병원

Ko En

Hematology-Oncology Kim, Ki Hyun M.D

Expertise
multiple myeloma, amyloidosis, bone marrow transplantation, CAR T-cell therapy
Treament Schedule 10 月
DATE
TUE
01
WEB
02
THU
03
FRI
04
SAT
05
SUN
06
MON
07
TUE
08
WEB
09
THU
10
FRI
11
SAT
12
SUN
13
MON
14
TUE
15
WEB
16
THU
17
FRI
18
SAT
19
SUN
20
MON
21
TUE
22
WEB
23
THU
24
FRI
25
SAT
26
SUN
27
MON
28
TUE
29
WEB
30
THU
31
AM
PM
Treament Schedule 11 月
DATE
FRI
01
SAT
02
SUN
03
MON
04
TUE
05
WEB
06
THU
07
FRI
08
SAT
09
SUN
10
MON
11
TUE
12
WEB
13
THU
14
FRI
15
SAT
16
SUN
17
MON
18
TUE
19
WEB
20
THU
21
FRI
22
SAT
23
SUN
24
MON
25
TUE
26
WEB
27
THU
28
FRI
29
SAT
30
AM
PM

Medical Education

2008 Ph.D. in Medicine Doctor of Philosophy, Graduate School, Chungbuk National University, Cheongju, Chungbuk, Korea
1991 Master of Science Master of Science, Graduate School, Seoul National University College of Medicine, Seoul, Korea

Post-Graduate Training

Fellowship   1999~2000 Samsung Medical Center
Residency   1995~1999 Samsung Medical Center
Internship   1991~1992 Seoul National University Hospital

Professional Appointments

2014~Present professor Department of Medicine Sungkyunkwan University School of Medicine
2008~2014 Associate professor Department of Medicine Sungkyunkwan University School of Medicine
2008~2009 Postdoc fellow Dana-Farber Cancer Institute
2002~2008 Assistant professor Division of Hematology/Oncology Department of Medicine Sungkyunkwan University School of Medicine Samsung Medical Center

Professional Memberships

Member Korean Cancer Association
Member American Society of Hematology
Member The International Myeloma Working Group (IMWG)
Member International Myeloma Society
Member International society of amyloidosis (ISA)

Selected Publications

  • JACC CARDIOVASC IMAGING 2021 Association of Left Ventricular Global Longitudinal Strain With Cardiac Amyloid Load in Light Chain Amyloidosis Kim1, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES
    View PubMed
  • LANCET 2021 10.1016/S0140-6736(21)00592-4 Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial Moreau1, P; Dimopoulos, MA; Mikhael, J; Yong, K; Capra, M; Facon, T; Hajek, R; Spicka, I; Baker, R; Kim, K; Martinez, G; Min, CK; Pour, L; Leleu, X; Oriol, A; Koh, Y; Suzuki, K; Risse, ML; Asset, G; Mace, S; Martin, T
    View PubMed
  • LEUKEMIA 2021 10.1038/s41375-021-01317-y A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis Dispenzieri1, A; Kastritis, E; Wechalekar, AD; Schonland, SO; Kim, K; Sanchorawala, V; Landau, HJ; Kwok, F; Suzuki, K; Comenzo, RL; Berg, D; Liu, GH; Kumar, A; Faller, DV; Merlini, G
    View PubMed
  • BRIT J HAEMATOL 2021 10.1111/bjh.17541 Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy Quach1, H; Nooka, A; Samoylova, O; Venner, CP; Kim, K; Facon, T; Spencer, A; Usmani, SZ; Grosicki, S; Suzuki, K; Delimpasi, S; Weisel, K; Obreja, M; Zahlten-Kumeli, A; Mateos, MV
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2019.367 Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia Cho1, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ
    View PubMed